MarketInOut Stock Screener Log In | Sign Up
 

Lantern Pharma Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Lantern Pharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9.49 mln
Float9.94 mln
Earnings Date11/11/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

11 / 100
Significantly lagging

ROE

-323
Deeply negative

ROA

-161
Deeply negative

Business Description

Lantern Pharma is a Dallas-based drug development company focused entirely on cancer treatment, using artificial intelligence to guide its research and improve the chances of success for its drug candidates. The company is advancing several drugs through clinical trials targeting difficult-to-treat cancers, including lung cancer, pancreatic cancer, brain tumors, and certain blood cancers. Lantern also works with a number of outside partners to expand its pipeline, combining its AI-driven approach with external expertise to develop treatments for both common and rare cancer types. Founded in 2013, the company continues to build on its technology platform to make cancer drug development faster and more precise.

Key Fundamentals

EPS-1.63
ROE-323
ROIC-5,799
ROA-161
EBITDA, mln-18.64
EV / EBITDA-0.21
EV / EBIT-0.21

Quote Details

Last 0.6354
Change -0.0053 (-0.83%)
Open 0.65
Volume 192,083
Turnover 122,050
Average Volume 332,820

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio1.81
Short % of Float3.26

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.94% 17 / 100   
1 Month -47.49% 5 / 100   
2 Months -78.46% 2 / 100   
6 Months -74.17% 5 / 100   
1 Year -83.67% 7 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog